ZURICH (Reuters) - Adding Herceptin to chemotherapy before surgery eradicates tumors in nearly three times as many women with inflammatory breast cancer as chemotherapy alone, the drug’s maker Roche Holding AG said on Wednesday.The results were from a clinical trial in women with inflammatory HER2-positive breast cancer, a rare but highly aggressive form of the disease, presented at the European Cancer Conference in Barcelona.
